Clerkenwell Health raises pre-seed funds and plans to open research facility

London-based psychedelic clinical research start-up is planning a seed funding round and has raised more than £700,000 in pre-seed funding, Tech Funding News has reported.

Investors in the company include New York City-based Vine Ventures and San Francisco-headquartered Lionheart Ventures, as well as a number of high-profile UK angel investors.

Clerkenwell Health is reported to be in discussions with drug developers looking at mood disorders, trauma-related conditions and addictions, and are exploring mental health conditions previously untargeted by psychedelic assisted treatments.

The company is also opening Europe’s first commercial facility dedicated to psychedelic assisted therapies in London in the summer and intends to begin trials in August focusing on the treatment for post-traumatic stress disorder and addiction.

Tom McDonald, chief executive of Clerkenwell Health, said: “Psychedelic assisted therapy could be groundbreaking for mental health treatment, and the UK is well-placed to be at the vanguard of that as a global leader in clinical trials post-Brexit. Clerkenwell Health’s aim is to establish the UK as the heart of the commercial psychedelic research ecosystem, working closely with mental health experts and drug developers around the world to tackle some of the most complex mental health conditions.”

Clerkenwell Health was founded last year by Sam Lewis, Dr Henry Fisher and McDonald, and its senior leadership team includes experts in psychiatry, psychedelics, clinical research and drugs development, advised by experts in mental health and psychedelics.

Date published: May 10, 2022

Subscriber content

To get unlimited access subscribe today

Subscribe

Already a subscriber? Login